<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assays of the renin-angiotensin-aldosterone system in adrenal disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assays of the renin-angiotensin-aldosterone system in adrenal disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Assays of the renin-angiotensin-aldosterone system in adrenal disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Stowasser, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Assessment of the renin-angiotensin-aldosterone system has assumed a much greater role in clinical practice, particularly in the evaluation of patients with hypertension. This is mainly attributable to the growing appreciation that primary aldosteronism is a much more common cause of hypertension than previously thought, accounting for as many as 5 to 10 percent of cases, and that most patients lack hypokalemia as a clinical clue. As a result, guidelines advocate screening for primary aldosteronism by measurement of plasma aldosterone and renin rather than that of plasma potassium (which is much less sensitive) and among a much wider population of individuals with hypertension than previously [<a href="#rid1">1</a>].</p><p>In addition, the renin-angiotensin-aldosterone system is often evaluated in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia or hyperkalemia who may have hyperaldosteronism (or other forms of real or apparent mineralocorticoid excess) or hypoaldosteronism, respectively</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal insufficiency (to distinguish primary from secondary)</p><p></p><p>The use of renin, angiotensin, and aldosterone measurements will be reviewed here. The approach to the patient with potential mineralocorticoid excess or hypoaldosteronism is discussed separately. (See  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a> and  <a class="medical medical_review" href="/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RENIN</span><span class="headingEndMark"> — </span>Renin can be measured in terms of its enzymatic activity (plasma renin activity [PRA]), or its mass (active renin concentration). (See  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Initial testing'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Plasma renin activity</span><span class="headingEndMark"> — </span>PRA is measured by incubating plasma at 37°C without addition of angiotensinogen (renin substrate), relying instead on endogenous angiotensinogen in the plasma [<a href="#rid2">2</a>]. Renin cleaves angiotensinogen to produce a decapeptide, angiotensin I, which can be measured by radioimmunoassay [<a href="#rid3">3</a>].</p><p>PRA is expressed as the amount of angiotensin I generated per unit of time. The recommended incubation time, 90 minutes, should be extended up to 18 hours for samples with levels less than 1 ng/mL/h, in order to permit enough generation of angiotensin I to ensure assay reproducibility at the lower end of the scale [<a href="#rid4">4</a>]. Subtracting the amount of preformed angiotensin I in a control aliquot incubated at 4°C is suggested, but this may reduce the reproducibility of the test [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Plasma renin concentration</span><span class="headingEndMark"> — </span>The plasma concentration of the active (cleaved) form of renin can be measured by radioimmunoassay but is usually measured by automated immunometric assay [<a href="#rid5">5</a>]. Since renin does not affect blood pressure directly, but only through angiotensin, PRA is a better reflection of angiotensin II concentrations. Active renin concentration can be influenced by substrate concentrations. As an example, with estrogen administration, substrate increases, and renin concentration falls to maintain angiotensin II concentrations in the normal range [<a href="#rid5">5</a>].</p><p>Automated immunometric assays for measuring active renin have been adopted in many laboratories because they are faster and more convenient than PRA or renin concentration radioimmunoassays. However, these methods are not yet sufficiently accurate to supplant PRA as a diagnostic test.</p><p class="headingAnchor" id="H191304688"><span class="h2">Which is the preferred assay?</span><span class="headingEndMark"> — </span>If available, PRA, although more time-consuming, is preferred over the direct active renin concentration for at least two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>PRA, unlike direct renin concentration, takes into account endogenous renin substrate (angiotensinogen) levels. This is important in the context of higher circulating <strong>estrogen</strong> (eg, women taking exogenous estrogen), which stimulates production of renin substrate. The resulting rise in angiotensin II (via angiotensin I) suppresses renal production of renin enzyme through a negative feedback mechanism, and direct renin concentration falls. In the face of raised substrate but reduced enzyme concentrations, PRA (angiotensin I generated by unit of time) remains relatively constant. As a result, when screening women receiving estrogen-containing preparations for the presence of primary aldosteronism by aldosterone/renin ratio testing, false-positive ratios can occur when renin is measured as direct renin concentration, but not when it is measured as PRA [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1">A sustained effect of the pre-ovulatory surge in estrogen is also thought to be responsible for the reported occurrence of false-positive aldosterone/renin ratios using direct renin concentration (but not PRA) during the luteal phase of the menstrual cycle [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns also exist about the reliability of the now widely used automated immunometric, chemiluminescent methods of measuring direct active renin concentration. This is particularly at the lower end of the clinical range, which is important when screening for primary aldosteronism using the aldosterone/renin ratio, a parameter that is dependent especially on the renin level. This may, in part, relate to the fact that these automated systems are calibrated by only a two-point recalibration against a stored master curve, contrasting with the multiple calibration points (permitting better curve resolution) used in each PRA assay.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Normal values</span><span class="headingEndMark"> — </span>Normal, morning PRA values for seated individuals range from approximately 1 to 4 ng/mL per hour (0.8 to 3.0 nmol/L per hour). Corresponding active renin concentrations are 8 to 35 mU/L.</p><p>Factors that affect renin levels include [<a href="#rid9">9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sodium intake – Renin may be stimulated by dietary salt restriction and suppressed by consumption of a high-salt diet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age – Renin levels gradually fall as renal function declines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex, menstrual phase, and pregnancy – Renin levels are higher in the luteal phase of the menstrual cycle and during pregnancy [<a href="#rid11">11,12</a>], in part because of the mineralocorticoid antagonist activity of progesterone (high concentrations of progesterone antagonize aldosterone action at the mineralocorticoid receptor). The rise in PRA during the luteal phase appears to be greater than that for direct renin concentration, probably because the late follicular surge in estrogen leads to a sustained rise in renin substrate (angiotensinogen) persisting into the luteal phase, resulting in higher angiotensin I and II, which in turn results in reduced renin enzyme production by negative feedback [<a href="#rid8">8</a>]. Menstruating women have lower renin levels during menses and the follicular (but not luteal) phases of the menstrual cycle when compared with age-matched men [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Time of day – Renin levels show a diurnal rhythm, being highest in the early morning upon awakening and falling during the day [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posture – Following assumption of upright posture, the translocation of blood into the lower limbs is associated with an increase in renin, released from juxtaglomerular cells in response to a fall in renal perfusion pressure and an increase in sympathetic output and beta-adrenergic receptor stimulation [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication use – Renin is increased with diuretics (including <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>), dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists. Levels are decreased by beta blockers, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, or alpha-methyldopa (all of which reduce beta-sympathetic stimulation of renin release), or nonsteroidal antiinflammatory agents (NSAIDs) (which promote salt retention and also inhibit renal prostaglandin production). Direct renin inhibitors lower PRA but raise direct renin concentration. In order to facilitate interpretation of aldosterone and renin levels, these agents should, when possible, be ceased for at least two and preferably four weeks (longer, eg, &gt;6 weeks, in the case of diuretics) before sample collection. During this period, antihypertensive medications that have minimal effects on renin (eg, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> slow release, to which can be added <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> and/or alpha blockers such as <a class="drug drug_general" data-topicid="9806" href="/d/drug information/9806.html" rel="external">prazosin</a> and/or moxonidine) can be used in place of the above interfering agents in order to maintain control of hypertension [<a href="#rid10">10,15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease – In chronic kidney disease, renal renin-producing capacity is reduced, and salt retention contributes to renin suppression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Race – Renin levels are lower in Black than White individuals [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Interpretation in adrenal disease</span><span class="headingEndMark"> — </span>Adrenal diseases have a variable effect on renin levels, being determined primarily by whether the disease results in an increase or a decrease in the secretion of mineralocorticoids (which induce volume expansion, resulting in suppression of renin release).</p><p>Renin levels are usually <strong>low</strong> in:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary aldosteronism, in which aldosterone production is excessive (relative to body sodium status), and independent of its normal regulator, renin/angiotensin [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Primary aldosteronism may be due to an aldosterone-producing adrenocortical tumor (adenoma or, rarely, carcinoma), bilateral adrenal hyperplasia, or glucocorticoid-remediable aldosteronism (familial hyperaldosteronism type I). (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a> and  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with 11-beta-hydroxylase or 17-alpha-hydroxylase deficiency (due to mutations in CYP11B1 and CYP17, respectively), which are hypertensive forms of congenital adrenal hyperplasia associated with excessive production of the mineralocorticoid deoxycorticosterone (DOC), driven by corticotropin (ACTH, levels of which are high as a result of deficient cortisol production). (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '11-beta-hydroxylase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary glucocorticoid resistance [<a href="#rid19">19</a>], which is again associated with ACTH simulation and excessive DOC production, causing hypertension. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with DOC-producing adrenal tumors [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ectopic ACTH syndrome [<a href="#rid21">21</a>], in which cortisol levels may be high enough to overwhelm the 11-beta-hydroxysteroid dehydrogenase type 2 enzyme (which normally, by converting cortisol to cortisone, prevents excessive stimulation of the mineralocorticoid receptor) [<a href="#rid21">21</a>]. In addition, the high levels of ACTH may lead to excessive production of DOC. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Ectopic ACTH syndrome'</a>.)</p><p></p><p>They are usually <strong>normal</strong> in:</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary adrenal insufficiency (ie, hypopituitarism or isolated ACTH deficiency). (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome, but they can be low when there is a marked degree of hypercortisolism. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p></p><p>They are usually <strong>high</strong> in:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary adrenal insufficiency, including Addison disease. (See  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with congenital adrenal hyperplasia due to deficiencies in either steroidogenic acute regulatory protein (StAR), side-chain cleavage enzyme (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (HSD3B2), 21-hydroxylase (CYP21A2) [<a href="#rid22">22</a>] or aldosterone synthase (CYP11B2) [<a href="#rid23">23</a>] in which deficient production of steroids with mineralocorticoid activity leads to salt wasting. (See  <a class="medical medical_review" href="/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Interpretation in nonadrenal conditions</span><span class="headingEndMark"> — </span>Renin levels are <strong>low</strong> in:</p><p class="bulletIndent1"><span class="glyph">●</span>Liddle syndrome, in which gain-of-function mutations in the epithelial sodium channel lead to sodium retention, hypertension, and usually hypokalemia [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital or acquired (eg, through ingestion of licorice) deficiency of 11-beta-hydroxysteroid dehydrogenase type 2, resulting in activation of the mineralocorticoid receptor by cortisol [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/2346.html" rel="external">"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations of the mineralocorticoid receptor gene, which cause a modest constitutive activation of the receptor, and permit progesterone and <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> to act as agonists rather than antagonists [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial hyperkalemic hypertension (also known as pseudohypoaldosteronism type 2 or Gordon syndrome), which is associated with sodium and potassium retention due to defects in genes encoding serine-threonine kinases (WNK1 and WNK4) [<a href="#rid28">28,29</a>] or ubiquitinating enzymes (CUL3 and KLCH3) [<a href="#rid30">30</a>] expressed in the distal nephron and altering expression of the sodium-potassium cotransporter. (See  <a class="medical medical_review" href="/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'</a>.)</p><p></p><p>Unlike primary aldosteronism, aldosterone concentrations are chronically suppressed (as a result of chronic suppression of renin secretion) in all of these salt-dependent, low-renin forms of hypertension, with the exception of familial hyperkalemic hypertension, in which chronically elevated plasma potassium concentrations limit suppression of aldosterone.</p><p>Renin levels are also often low in patients with chronic kidney disease, in which reduced renin-producing capacity and salt retention contribute to renin suppression [<a href="#rid31">31</a>].</p><p>Renin levels are <strong>high</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with "renovascular" forms of hypertension and reninoma (levels may also be normal).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In malignant hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In pseudohypoaldosteronism type 1, in which salt wasting occurs due to resistance to the actions of aldosterone, resulting from mutations in the gene encoding the epithelial sodium channel (autosomal recessive) or mineralocorticoid receptor (autosomal dominant or sporadic). (See  <a class="medical medical_review" href="/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1", section on 'Pseudohypoaldosteronism type 1'</a> and  <a class="medical medical_review" href="/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Bartter and Gitelman syndromes, in which mutations in renal tubular ion channels also lead to salt wasting. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In heart failure, hepatic cirrhosis, and nephrotic syndrome, in which edema is associated with relative intravascular hypovolemia [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">ALDOSTERONE</span><span class="headingEndMark"> — </span>Serum aldosterone is measured by radioimmunoassay [<a href="#rid32">32</a>]. The assay requires a high-affinity, highly specific antibody because aldosterone concentrations in serum are less than 1 percent those of cortisol. Faster, more convenient methods of directly measuring aldosterone are available, using immunometric techniques and automated machinery [<a href="#rid33">33</a>].</p><p>Like the automated active renin concentration assay, considerable work is required to validate and improve these methods before they can be considered accurate enough to use for diagnostic purposes (eg, evaluating patients for possible primary aldosteronism).</p><p>Concerns with the <strong>automated</strong> aldosterone assay include:</p><p class="bulletIndent1"><span class="glyph">●</span>Potential for false-negative suppression tests. In an analysis, aldosterone levels were below the assay's limit of detection for over half the samples collected from normal subjects and nearly half those from patients with primary hypertension (formerly called "essential" hypertension) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific interference, possibly due to the brevity of the "wash" immediately prior to chemiluminescence, leading to an unacceptably high "blank" value in bilaterally adrenalectomized and Addisonian patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weaknesses of the assay system: It is calibrated by only a two-point recalibration against a stored master curve, and the two calibrators are reconstituted lyophilized aldosterone. Inclusion of blanks using plasma from bilaterally adrenalectomized or Addisonian patients, as well as calibration using plasma pools from persons with known low, medium or high values, would permit very valuable, in-house, ongoing evaluation of the system.</p><p></p><p>Highly accurate and reproducible methods of measuring aldosterone using high-performance liquid chromatography and tandem mass spectrometry have been developed [<a href="#rid35">35</a>] and are now in clinical use. The incorporation of new semi-automated technology has meant that these methods can generate results rapidly and with relatively high throughput.</p><p class="headingAnchor" id="H10"><span class="h2">Normal values</span><span class="headingEndMark"> — </span>Morning serum (and plasma) aldosterone concentrations range from 5 to 30 ng/dL (140 to 830 pmol/L) in seated, healthy individuals with unrestricted salt intakes [<a href="#rid36">36</a>]. Concentrations are lower in Black than in White individuals [<a href="#rid37">37</a>]. Other aspects that affect aldosterone concentrations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Diurnal variation – There is a diurnal variation in serum aldosterone concentrations, with highest concentrations at approximately the time of awakening and lowest in the evening [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extracellular fluid volume – Serum aldosterone concentrations are normally related to extracellular fluid volume, being increased by dehydration, dietary sodium restriction, or sodium diuresis, and decreased by oral or intravenous sodium loading.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma potassium concentration – Aldosterone concentrations are also related to plasma potassium concentrations, being increased by hyperkalemia and decreased by hypokalemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Menstrual phase and pregnancy – Aldosterone concentrations tend to be increased in the luteal phase of the menstrual cycle (during which they are significantly higher than in age-matched males) [<a href="#rid8">8</a>] and are increased up to 10 times normal by the third trimester of pregnancy [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posture – Following assumption of upright posture, the translocation of blood into the lower limbs is associated with a rise in plasma aldosterone [<a href="#rid39">39</a>]. This results partly from an increase in renin [<a href="#rid14">14</a>]. In addition, reduced metabolic clearance of aldosterone occurs due to reduced hepatic blood flow [<a href="#rid14">14</a>].</p><p></p><p>In practice, for most situations where aldosterone and renin levels are to be assessed, most centers draw a morning, ambulatory, upright sample. </p><p class="headingAnchor" id="H11"><span class="h2">Interpretation in adrenal disease</span><span class="headingEndMark"> — </span>Serum aldosterone levels are usually <strong>low</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with 11-beta-hydroxylase or 17-alpha-hydroxylase deficiencies [<a href="#rid40">40,41</a>], which are associated with excessive production of deoxycorticosterone (DOC) (and possibly corticosterone in the latter condition).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients with Cushing syndrome, with the extent of suppression depending upon the degree of hypersecretion of cortisol and other salt-retaining steroids.</p><p></p><p>Serum aldosterone levels are usually <strong>low</strong> <strong>or undetectable</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>In primary adrenal insufficiency and may be normal or low in patients with chronic corticotroph deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with deficiencies of either steroidogenic acute regulatory protein (StAR), side-chain cleavage enzyme, 3-beta-hydroxysteroid dehydrogenase, and aldosterone synthase since aldosterone synthesis is directly impaired [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p></p><p>Levels are <strong>high</strong> in:</p><p class="bulletIndent1"><span class="glyph">●</span>Many patients with primary aldosteronism but are often normal (inappropriately, in the face of renin suppression) [<a href="#rid10">10,14</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Interpretation in other (nonadrenal) conditions</span><span class="headingEndMark"> — </span>Aldosterone levels may be <strong>low</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with Liddle syndrome, 11-beta-hydroxysteroid dehydrogenase deficiency, primary glucocorticoid resistance, 11-beta-hydroxylase and 17-alpha-hydroxylase deficiencies, ectopic corticotropin (ACTH) syndrome, or activating mutations of the mineralocorticoid receptor. (See <a class="local">'Interpretation in nonadrenal conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In hyporeninemic hypoaldosteronism associated with diabetic nephropathy and some other renal disorders. (See  <a class="medical medical_review" href="/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Or normal in pseudohypoaldosteronism type 2. (See <a class="local">'Interpretation in nonadrenal conditions'</a> above.)</p><p></p><p>Levels may be <strong>high</strong> in patients with secondary hyperaldosteronism in which raised aldosterone is secondary to raised renin/angiotensin levels:</p><p class="bulletIndent1"><span class="glyph">●</span>In renal artery stenosis or reninoma (causing renin-dependent hypertension).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In malignant hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In pseudohypoaldosteronism type 1 (resulting in resistance to aldosterone action). (See  <a class="medical medical_review" href="/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1", section on 'Pseudohypoaldosteronism type 1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In heart failure, cirrhosis, and nephrotic syndrome, in which edema is associated with relative intravascular hypovolemia and (in the case of heart failure and hepatic cirrhosis) aldosterone metabolism may be impaired [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients receiving diuretic medications (including <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>) or preparations containing progesterone or <a class="drug drug_general" data-topicid="121397" href="/d/drug information/121397.html" rel="external">drospirenone</a> (both of which antagonize aldosterone action at the level of the mineralocorticoid receptor) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Or normal in Bartter syndrome and Gitelman syndrome, in which hypokalemia limits the aldosterone rise that results from stimulation by raised renin levels.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Urine aldosterone excretion</span><span class="headingEndMark"> — </span>Aldosterone, in the form of its 18-glucuronide, is measured by radioimmunoassay. Its excretion varies from approximately 5 to 19 mcg (14 to 53 nmol) per 24 hours. The excretion of tetrahydroaldosterone-18-glucuronide, a more abundant metabolite, ranges from approximately 12 to 65 mcg (33 to 178 nmol) per 24 hours.</p><p>As with aldosterone/renin ratio testing, diuretics (including <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>) should be withheld for at least six weeks before testing, and beta-blockers, <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, direct renin inhibitors, and nonsteroidal antiinflammatory drugs (NSAIDs) for at least two weeks (and preferably four) before urinary aldosterone excretion is measured. Hypokalemia should be corrected with <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> (KCl) supplements, and the patient should be instructed to follow a diet with a liberal sodium intake.</p><p>Urinary aldosterone excretion varies in patients with adrenal disease in a manner similar to that described above for serum aldosterone.</p><p class="headingAnchor" id="H14"><span class="h2">Aldosterone secretory rate</span><span class="headingEndMark"> — </span>Aldosterone secretion or production rates can be measured by isotopic dilution methods [<a href="#rid18">18,40</a>]. Aldosterone, labeled with a radioactive or nonradioactive isotope, is injected intravenously. Either a series of blood samples or a 24-hour urine collection is then obtained. The extent of dilution of labeled aldosterone by endogenous unlabeled aldosterone (ie, the decrease in specific activity) is determined and can be used to calculate the amount of endogenous aldosterone secreted during the interval.</p><p>Because these assays are technically demanding, time-consuming, and expensive and the information required for clinical decisions can usually be obtained by other means, steroid secretion rates are rarely measured nowadays.</p><p class="headingAnchor" id="H3560196840"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114450.html" rel="external">"Society guideline links: Primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical uses</strong> – Assessment of the renin-angiotensin-aldosterone system has assumed a much greater role in clinical practice, particularly in the evaluation of patients with hypertension. This is mainly attributable to the growing appreciation that primary aldosteronism is a much more common cause of hypertension than previously thought, accounting for as many as 5 to 10 percent of cases, and that most patients lack hypokalemia as a clinical clue. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a>.)</p><p></p><p class="bulletIndent1">In addition, the renin-angiotensin-aldosterone system is often evaluated in patients with hypokalemia or hyperkalemia who may have hyperaldosteronism (or other forms of real or apparent mineralocorticoid excess) or hypoaldosteronism, respectively, and adrenal insufficiency (to distinguish primary from secondary). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renin measurement</strong> – Renin can be measured in terms of its enzymatic activity (plasma renin activity [PRA]) or its mass (active renin concentration). (See <a class="local">'Renin'</a> above and  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Initial testing'</a>.)</p><p></p><p class="bulletIndent1">Normal, morning PRA values for seated individuals range from approximately 1 to 4 ng/mL per hour (0.8 to 3.0 nmol/L per hour). Levels may be affected by sodium intake, age, time of day, upright posture, medication use, and endogenous progesterone. (See <a class="local">'Normal values'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aldosterone measurement</strong> – Morning serum (and plasma) aldosterone concentrations range from 5 to 30 ng/dL (140 to 830 pmol/L) in seated, healthy individuals with unrestricted salt intakes. Like PRA, aldosterone levels are affected by sodium intake, time of day, upright posture, and endogenous progesterone. (See <a class="local">'Normal values'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889.</a></li><li><a class="nounderline abstract_t">Haber E, Koerner T, Page LB, et al. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969; 29:1349.</a></li><li><a class="nounderline abstract_t">Workman RJ, Sussman CR, Burkitt DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med 1979; 93:847.</a></li><li><a class="nounderline abstract_t">Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med 1975; 5:189.</a></li><li><a class="nounderline abstract_t">Ferrari P, Shaw SG, Nicod J, et al. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22:377.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Gordon RD, Taylor PJ, et al. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96:1797.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Gordon RD, Ward G, et al. Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. J Clin Endocrinol Metab 2017; 102:2329.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Gordon RD, Taylor PJ, et al. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab 2011; 96:E340.</a></li><li><a class="nounderline abstract_t">Laragh JH, Sealey J, Brunner HR. The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. Am J Med 1972; 53:649.</a></li><li><a class="nounderline abstract_t">Stowasser, M, Gordon, RD. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist 2004; 14:267.</a></li><li><a class="nounderline abstract_t">Michelakis AM, Yoshida H, Dormois JC. Plasma renin activity and plasma aldosterone during the normal menstrual cycle. Am J Obstet Gynecol 1975; 123:724.</a></li><li><a class="nounderline abstract_t">Weinberger MH, Kramer NJ, Grim CE, Petersen LP. The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women. J Clin Endocrinol Metab 1977; 44:69.</a></li><li><a class="nounderline abstract_t">Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966; 45:1587.</a></li><li><a class="nounderline abstract_t">Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18:495.</a></li><li><a class="nounderline abstract_t">Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Gordon RD, Ward G, et al. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. J Clin Endocrinol Metab 2017; 102:2039.</a></li><li><a class="nounderline abstract_t">Sever PS, Peart WS, Meade TW, et al. Ethnic differences in blood pressure with observations on noradrenaline and renin. 1. A working population. Clin Exp Hypertens 1979; 1:733.</a></li><li><a class="nounderline abstract_t">CONN JW. PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM. IMPORTANCE IN DIFFERENTIAL DIAGNOSIS AND IN RESEARCH OF ESSENTIAL HYPERTENSION. JAMA 1964; 190:222.</a></li><li><a class="nounderline abstract_t">Arai K, Chrousos GP. Syndromes of glucocorticoid and mineralocorticoid resistance. Steroids 1995; 60:173.</a></li><li><a class="nounderline abstract_t">Irony I, Biglieri EG, Perloff D, Rubinoff H. Pathophysiology of deoxycorticosterone-secreting adrenal tumors. J Clin Endocrinol Metab 1987; 65:836.</a></li><li><a class="nounderline abstract_t">Walker BR, Campbell JC, Fraser R, et al. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992; 37:483.</a></li><li><a class="nounderline abstract_t">Simpoulos AP, Marshall JR, Delea CS, Bartter FC. Studies on the deficiency of 21-hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1971; 32:438.</a></li><li><a class="nounderline abstract_t">Shizuta Y, Kawamoto T, Mitsuuchi Y, et al. Inborn errors of aldosterone biosynthesis in humans. Steroids 1995; 60:15.</a></li><li><a class="nounderline abstract_t">Warnock DG. Liddle syndrome: genetics and mechanisms of Na+ channel defects. Am J Med Sci 2001; 322:302.</a></li><li><a class="nounderline abstract_t">Stewart PM. 11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Clin Endocrinol (Oxf) 1996; 44:493.</a></li><li><a class="nounderline abstract_t">White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am 1994; 23:325.</a></li><li><a class="nounderline abstract_t">Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119.</a></li><li><a class="nounderline abstract_t">Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19:287.</a></li><li><a class="nounderline abstract_t">Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293:1107.</a></li><li><a class="nounderline abstract_t">Boyden LM, Choi M, Choate KA, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482:98.</a></li><li><a class="nounderline abstract_t">McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952.</a></li><li><a class="nounderline abstract_t">Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab 1970; 30:682.</a></li><li><a class="nounderline abstract_t">Perschel FH, Schemer R, Seiler L, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50:1650.</a></li><li><a class="nounderline abstract_t">Schirpenbach C, Seiler L, Maser-Gluth C, et al. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52:1749.</a></li><li><a class="nounderline abstract_t">Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009; 55:1155.</a></li><li><a class="nounderline abstract_t">Al-Dujaili EA, Edwards CR. The development and application of a direct radioimmunoassay for plasma aldosterone using 125I-labeled ligand--comparison of three methods. J Clin Endocrinol Metab 1978; 46:105.</a></li><li><a class="nounderline abstract_t">Pratt JH, Jones JJ, Miller JZ, et al. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med 1989; 321:1152.</a></li><li><a class="nounderline abstract_t">Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40:125.</a></li><li><a class="nounderline abstract_t">Tuck ML, Dluhy RG, Williams GH. Sequential responses of the renin-angiotensin-aldosterone axis to acute postural change: effect of dietary sodium. J Lab Clin Med 1975; 86:754.</a></li><li><a class="nounderline abstract_t">Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56:222.</a></li><li><a class="nounderline abstract_t">D'Armiento M, Reda G, Kater C, et al. 17 alpha-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family. J Clin Endocrinol Metab 1983; 56:697.</a></li></ol></div><div id="topicVersionRevision">Topic 167 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26934393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4311082" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/570999" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/164697" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radioimmunoassay of plasma renin activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15076197" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21411552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379474" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962019" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4342888" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The aldosterone-renin ratio for screening for primary aldosteronism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1200065" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Plasma renin activity and plasma aldosterone during the normal menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/833263" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4288714" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A diurnal rhythm in plasma renin activity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9221268" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552288" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324033" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/399455" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ethnic differences in blood pressure with observations on noradrenaline and renin. 1. A working population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14246593" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM. IMPORTANCE IN DIFFERENTIAL DIAGNOSIS AND IN RESEARCH OF ESSENTIAL HYPERTENSION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7792808" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Syndromes of glucocorticoid and mineralocorticoid resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2822755" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pathophysiology of deoxycorticosterone-secreting adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1337504" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4322392" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Studies on the deficiency of 21-hydroxylation in patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7792802" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inborn errors of aldosterone biosynthesis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11780687" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Liddle syndrome: genetics and mechanisms of Na+ channel defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8762725" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8070425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Steroid 11 beta-hydroxylase deficiency and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884226" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5490655" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11498583" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Human hypertension caused by mutations in WNK kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939533" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5444558" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A radioimmunoassay for plasma aldosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247156" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16858077" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359537" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/752013" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The development and application of a direct radioimmunoassay for plasma aldosterone using 125I-labeled ligand--comparison of three methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677724" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Racial differences in aldosterone excretion and plasma aldosterone concentrations in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1112870" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1185036" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sequential responses of the renin-angiotensin-aldosterone axis to acute postural change: effect of dietary sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6296182" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300162" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : 17 alpha-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
